Autopsy report · NCT01470742

Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“We stop because of problems such as insurance.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: Samsung Medical Center
Sponsor type: University, hospital or other
Conditions: Gastric Cancer
Interventions: XELOX; XELODA
Participants: 0
Sites: 1
Countries: South Korea

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.